Financial Performance - The company reported a total revenue of 6,630,326.70 RMB from government subsidies related to normal business operations[21]. - The company's operating revenue for the first half of 2024 was CNY 1,154,413,477.20, a slight increase of 0.10% compared to CNY 1,153,217,104.50 in the same period last year[36]. - Net profit attributable to shareholders was CNY 331,871,287.24, reflecting a growth of 3.12% from CNY 321,841,708.90 year-on-year[36]. - The net profit after deducting non-recurring gains and losses was CNY 318,600,238.56, up by 5.28% from CNY 302,626,154.93 in the previous year[36]. - The company's revenue for the reporting period was approximately CNY 1.15 billion, a slight increase of 0.10% compared to the previous year[53]. - The pharmaceutical segment generated revenue of CNY 1.136 billion, with a net profit of CNY 631 million, reflecting a year-on-year increase of 0.47% and 0.30% respectively[72]. - The company achieved a total revenue of CNY 1.154 billion in the reporting period, representing a year-on-year growth of 0.10%[72]. Non-Recurring Gains and Losses - The total non-recurring gains and losses amounted to 13,271,048.68 RMB after tax impacts and minority interests[21]. Research and Development - The company has maintained a strong commitment to R&D in children's health, enhancing its competitive edge[24]. - Research and development investment increased by 67.99% to approximately CNY 49.05 million, primarily due to an increase in R&D personnel[53]. - The company is focusing on the development of children's medications, supported by recent government policies aimed at enhancing the R&D and production of pediatric drugs[39]. - The company aims to launch 1 to 2 new pediatric drug varieties each year, enhancing its product matrix[4]. - The company plans to enhance its R&D efforts for new drugs, focusing on unique core technologies for children's medications, including innovative formulations and taste-masking techniques[99]. - The company has established a comprehensive children's drug product system through collaboration with universities and research institutions[50]. Market Position and Strategy - The company continues to lead the children's pharmaceutical industry in China, focusing on children's health products since 2007[24]. - The brand "Yikexin" remains the market leader in children's health products, with a significant market share[24]. - The company is actively pursuing market expansion strategies to strengthen its position in the children's healthcare sector[24]. - The company continues to lead the market with its flagship product, E-Care Vitamin AD, maintaining the highest market share in its category[4]. - The marketing strategy focuses on expert recommendations and convenient purchasing channels, adapting to market changes[49]. - The company has strengthened its marketing strategy, expanding the target age for its product "Yike Xin" to 0-18 years[72]. Financial Position - Total assets at the end of the reporting period were CNY 4,777,770,975.97, down 8.09% from CNY 5,198,294,479.89 at the end of the previous year[36]. - Net assets attributable to shareholders decreased by 4.59%, totaling CNY 2,845,093,487.55 compared to CNY 2,981,885,170.31 at the end of the last year[36]. - The total current assets decreased from 3,704,884,921.76 RMB to 3,304,920,737.19 RMB, a decline of approximately 10.8%[174]. - The total non-current assets decreased from 1,493,409,558.13 RMB to 1,472,850,238.78 RMB, a decline of about 1.4%[174]. - The total liabilities decreased from CNY 701,652,154.75 to CNY 623,386,969.58, a reduction of approximately 11.2%[196]. - Shareholders' equity decreased from CNY 4,496,642,325.14 to CNY 4,154,384,006.39, a decline of about 7.6%[196]. Cash Flow - The net cash flow from operating activities decreased by 29.43%, amounting to CNY 417,869,236.68 compared to CNY 592,107,241.53 in the same period last year[36]. - The net cash flow from investing activities increased by 177.21% to approximately $320.87 million, primarily due to the net redemption of structured deposits held by banks[54]. - The net cash flow from financing activities decreased by 40.10% to approximately -$973.08 million, mainly due to an increase in dividends paid[54]. - The net increase in cash and cash equivalents was approximately -$234.34 million, a 54.76% improvement compared to the previous period, influenced by the net redemption of structured deposits and increased dividends[54]. Compliance and Governance - The company has ensured compliance with all regulatory commitments and has no outstanding obligations as of the reporting date[26]. - The company has not reported any discrepancies between domestic and international accounting standards for the reporting period[19]. - The company is committed to enhancing its internal control systems and governance capabilities as part of its strategic focus on core pharmaceutical operations[72]. Environmental Responsibility - In the first half of 2024, Dain Pharmaceutical invested approximately 1.15 million in environmental governance and protection[119]. - During the reporting period, Dain Pharmaceutical's wastewater treatment system operated smoothly, with COD at 23.4 mg/L and ammonia nitrogen at 1.24 mg/L, both meeting the GB/T 31962-2015 standards[133]. - The company has implemented a self-monitoring plan for environmental protection, ensuring compliance with various environmental standards[119]. - Dain Pharmaceutical has actively participated in national public welfare activities, including the "Children's Safe Medication Science Community Tour" and "Height Management Free Clinic in Communities"[120]. - Dain Pharmaceutical has initiated the "AD Guardian Plan" to support children's growth and development through public welfare activities[120]. Legal and Administrative Matters - The company is involved in a lawsuit concerning the unauthorized use of its assets, with a claim amounting to 12.06 million[140]. - The company reported a total external guarantee amount of 134.51 million yuan, which accounts for 0.05% of the company's net assets[146]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[119]. - The company has not engaged in any significant related party transactions or asset acquisitions during the reporting period[128][129]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 19,270, with the largest shareholder, Shandong Huate Holding Group Co., Ltd., holding 22.00% of shares, totaling 51,544,340 shares[167]. - The company's total share capital as of June 30, 2024, is 234,331,485 shares, which serves as the basis for the upcoming dividend distribution[109]. - The company reported a cash dividend of 5 CNY per 10 shares, totaling 117,165,742.50 CNY, which represents 100% of the distributable profit[109].

Summary of the Conference Call for Huatai Printing Company Company Overview - **Company**: Huatai Printing Company - **Industry**: Pharmaceutical Manufacturing Key Points and Arguments Industry Performance - The pharmaceutical manufacturing industry experienced a decline in revenue of 1% and a slight increase in total profit of 0.3% from January to May 2024, indicating an overall unfavorable industry outlook [1][2]. Company Strategy - Huatai Printing is focusing on its core pharmaceutical business, enhancing technological innovation, and exploring digital transformation while emphasizing compliance and risk control [2]. - The company has made progress in divesting non-core businesses, with a recent material company entering self-dissolution and liquidation [2]. Research and Development - The company is committed to developing pediatric medications tailored to clinical needs, with five pediatric drug projects included in the Ministry of Science and Technology's major special projects [2]. Production and Marketing - The company employs a sales-driven production strategy to ensure quality and market supply, while also enhancing automation and intelligence in production [3]. - Marketing strategies include expanding the promotion of specific products based on clinical expert consensus and strengthening partnerships with key distributors and large chains [3]. Brand Development - Huatai Printing has been recognized in the 2023 China Pharmaceutical Industry Top 100 list, and its product, Yikexin, won awards in the 2024 China Pharmaceutical Brand Awards [4]. Financial Performance - For the first half of 2024, the company reported revenue of 1.154 billion yuan, a 0.1% increase year-over-year, and a net profit of 332 million yuan, a 3.12% increase year-over-year. The pharmaceutical business generated revenue of 1.136 billion yuan and a net profit of 631 million yuan, reflecting growth of 0.44% and 0.32%, respectively [5]. Market Challenges - The retail pharmaceutical sector is facing significant pressure due to an increase in the number of retail pharmacies, which has risen from approximately 470,000 pre-pandemic to nearly 700,000, leading to increased operational and cost pressures for individual stores [10]. - Despite declining consumer spending, there is a potential for brand products to gain prominence as the number of pharmacies decreases [11]. Pediatric and Nutritional Products - The growth of pediatric and nutritional products is under pressure due to lower birth rates and environmental factors, but there is confidence in future growth driven by increased awareness of children's health needs [12][16]. Policy Impact - Current pricing policies for designated pharmacies have not significantly impacted the company's operations, and the use of medical insurance for retail pharmacy purchases remains low [17][18]. Market Environment and Sales Channels - Online sales have shown significant growth, while sales through medical institutions have decreased to about 12% of total sales, with the remaining 88% coming from external channels [23]. - The company is actively engaging in targeted advertising through various media, including smart TV ads, to reach specific demographics [21]. Future Outlook - The company maintains its annual guidance for a 10% growth rate and aims to sustain a high dividend payout ratio [24][25]. - There is optimism for the second half of the year, with expectations for improved performance driven by ongoing marketing efforts and product promotions [38]. Additional Important Information - The company is preparing for board member elections scheduled for August 17, 2024, in accordance with regulatory requirements [35].

Group 1: Financial Performance - The company achieved a revenue of 11.54 billion, an increase of 3.32 billion compared to the same period last year, representing a growth of 3.32% [3] - The net profit attributable to shareholders reached 6.31 billion, reflecting a growth of 0.44% compared to the previous year [3] - The pharmaceutical business generated significant revenue, with a focus on children's health products [3] Group 2: Market Trends and Challenges - The pharmaceutical manufacturing industry saw a revenue decline of 0.3% from January to May 2024, indicating a challenging market environment [3] - The retail pharmacy sector is experiencing rapid expansion, with approximately 670,000 stores by the end of 2023, leading to increased operational pressures [4] - The growth of children's and adult medications is under pressure, with only a slight increase in birth rates observed [4] Group 3: Strategic Initiatives - The company is focusing on digital transformation and compliance risk management to strengthen its core pharmaceutical business [3] - Five children's drug R&D projects have been included in major national initiatives, emphasizing the company's commitment to innovation [3] - Marketing strategies are being adjusted to enhance product promotion and distribution, including partnerships with key distributors and retail chains [3] Group 4: Future Outlook - The company aims for a revenue and net profit growth target of 10% for 2024, with no revisions to the performance guidance [4] - Plans for increased advertising and promotional activities are in place to drive growth in the second half of the year [5] - The company is optimistic about achieving its annual operational goals through expert consensus and targeted marketing efforts [8]

证券代码：000915 证券简称：华特达因 公告编号：2024-020 山东华特达因健康股份有限公司 2024 年 7 月 8 日，沂南华特卧龙学校收到山东省沂南县人民法 院送达的《民事裁定书》（2024）鲁 1321 民初 296 号之二和《民事 裁定书》（2024）鲁 1321 民初 296 号。 1.《民事裁定书》(2024）鲁 1321 民初 296 号之二的裁定如下： 本案恢复诉讼。裁定书落款日期为二〇二四年六月二十七日。 2.《民事裁定书》（2024）鲁 1321 民初 296 号的裁定如下： 驳回沂南华特卧龙学校的起诉。裁定书落款日期为二〇二四年七月二 日。 关于沂南华特卧龙学校诉讼的进展公告 三、其他尚未披露的诉讼仲裁事项 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 截止本公告披露日，公司及控股子公司其他未裁决的小额诉讼、 仲裁涉及金额共计约 76 万元。 一、有关本案的基本情况 2024 年 1 月，公司子公司沂南华特卧龙学校因沂南县教育和体 育局、山东沂南县第二中学、沂南县卧龙学校及沂南县育新实验学校 在未经沂南华特卧龙学校同意的情况下 ...

Financial Performance - The company achieved total operating revenue of 1.154 billion yuan, a slight increase of 0.10% compared to the same period last year[2] - Net profit attributable to shareholders reached 331.87 million yuan, reflecting a growth of 3.12% year-on-year[2] - The pharmaceutical segment generated operating revenue of 1.136 billion yuan, with a net profit of 631 million yuan, marking increases of 0.44% and 0.32% respectively[3] - Basic earnings per share increased to 1.42 yuan, up by 3.65% from the previous year[2] - The net profit after deducting non-recurring gains and losses was 318.60 million yuan, an increase of 5.28% year-on-year[2] Asset and Equity Changes - Total assets decreased by 8.09% to approximately 4.778 billion yuan compared to the beginning of the period[2] - Shareholders' equity attributable to the company declined by 4.59% to approximately 2.845 billion yuan[2] - The company's net asset per share decreased to 12.14 yuan, down by 4.63% from the previous year[2] Return on Investment - The weighted average return on net assets decreased by 1.05 percentage points to 10.81%[2] Information Disclosure - The company emphasizes the importance of accurate information disclosure and warns investors of potential risks associated with preliminary financial data[1]

证券代码：000915 证券简称：华特达因 公告编号：2024-019 本案在审理过程中，被告沂南县教育和体育局申请法院对沂南华 特卧龙学校给予强制清算。 本院经审查认为，被告沂南县教育和体育局申请法院对沂南华特 卧龙学校给予强制清算，本案应中止审理。 山东华特达因健康股份有限公司 关于沂南华特卧龙学校诉讼的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、有关本案的基本情况 2024 年 1 月，公司子公司沂南华特卧龙学校因沂南县教育和体 育局、山东沂南县第二中学、沂南县卧龙学校及沂南县育新实验学校 在未经沂南华特卧龙学校同意的情况下，实际占有并使用沂南华特卧 龙学校全部资产（包括学校场地、教室、教育教学设备等）用于办学 的事项，向山东省沂南县人民法院提起诉讼。具体情况详见 2024 年 1 月 9 日刊登于巨潮资讯网（http://www.cninfo.com.cn）上的《关 于沂南华特卧龙学校提起诉讼的公告》（公告编号：2024-001）。 二、本案诉讼的进展情况 近日，沂南华特卧龙学校收到山东省沂南县人民法院送达的《民 事裁定书》(2024 ...

证券代码：000915 证券简称：华特达因 公告编号：2024-018 山东华特达因健康股份有限公司关于控股子公司山东华特 知新材料有限公司解散清算暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 （一）山东华特达因健康股份有限公司（以下简称"公司"或"华 特达因"）第十届董事会 2024 年第一次临时会议审议通过了"关于 山东华特知新材料有限公司解散清算暨关联交易的议案"，同意控股 子公司山东华特知新材料有限公司（以下简称"华特知新公司"）进 行解散清算。 （二）华特知新公司的一方股东浪潮数字（山东）科技有限公司 （以下简称"浪潮数字公司"）是浪潮集团有限公司的全资子公司， 浪潮集团有限公司与公司大股东山东华特控股集团有限公司的控股 股东同为山东省国有资产投资控股有限公司。根据《深圳证券交易所 股票上市规则》等相关规定，浪潮数字公司为公司关联法人，公司与 关联方共同投资的华特知新材料公司的解散清算构成关联交易。 （三）公司第十届董事会 2024 年第一次临时会议审议该解散清 算暨关联交易议案时，关联董事朱效平进行了回避表决。 ...

本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：000915 证券简称：华特达因 公告编号：2024-017 山东华特达因健康股份有限公司 第十届董事会 2024 年第一次临时会议决议公告 山东华特达因健康股份有限公司第十届董事会于 2024 年 5 月 28 日以电子邮件形式发出召开第十届董事会 2024 年第一次临时会议的 通知，并于 2024 年 5 月 31 日在公司会议室召开会议。会议由董事长 朱效平先生主持，应参加董事 8 名，实际参加董事 8 名，公司全体监 事列席会议。会议符合有关法律、法规、规章和《公司章程》的规定。 二、董事会会议审议情况 会议以 7 票同意 0 票弃权 0 票反对的表决结果，审议通过了"关 于山东华特知新材料有限公司解散清算暨关联交易的议案"：同意控 股子公司山东华特知新材料有限公司进行解散清算。 关联董事朱效平在董事会审议该关联交易时，回避表决。 特此公告 由全体独立董事参加的公司独立董事 2024 年第一次专门会议就 该议案进行了事前审核，一致同意将议案提交董事会审议； 由全体独立董事 ...

一、股东大会审议通过的利润分配方案情况 1．山东华特达因健康股份有限公司（以下简称"本公司"或"公司"） 于 2024 年 4 月 16 日召开公司 2023 年年度股东大会，审议通过了"公 司 2023 年度利润分配及资本公积金转增股本预案"：以 2023 年 12 月 31 日的总股本 234,331,485 股为基数，向公司全体股东每 10 股派发 现金红利 20.00 元（含税），不以资本公积金转增股本。 2．公司本次利润分配为固定比例方式分配。自分配方案披露至 实施期间，公司股本总额未发生变化。 3．本次实施的分配方案与公司 2023 年年度股东大会审议通过的 方案一致。 4．本次实施分配方案距离股东大会审议通过的时间未超过两个 月。 证券代码：000915 股票简称：华特达因 编号：2024-016 山东华特达因健康股份有限公司 2023 年度分红派息实施公告 本公司及其董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 1.本公司此次委托中国结算深圳分公司代派的A股股东现金红利 将于2024年5月16日通过股东托管证券公司（或其他托管机构）直接 划入其资金账 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [7][24]. Core Insights - The company achieved revenue of 572 million yuan in Q1 2024, representing a year-on-year growth of 1.85%. The net profit attributable to the parent company was 169 million yuan, up 3.00% year-on-year, while the net profit excluding non-recurring items was 162 million yuan, reflecting a growth of 4.99% year-on-year [1]. - The company is focusing on core business areas and enhancing its innovation capabilities, which is expected to drive internal growth. The product portfolio is becoming increasingly comprehensive, leading to a maintained "Buy" rating [24]. - The company has made significant advancements in automation and digitalization in its production processes, including the installation of a new intelligent automatic packaging line, which has improved production capacity and efficiency [2]. Financial Performance - The projected revenue for the company from 2024 to 2026 is expected to be 2.869 billion yuan, 3.262 billion yuan, and 3.592 billion yuan, respectively, with corresponding net profits of 708 million yuan, 808 million yuan, and 893 million yuan [24]. - The company’s earnings per share (EPS) are forecasted to increase from 2.50 yuan in 2023 to 3.81 yuan in 2026, indicating a positive growth trajectory [25]. - The return on equity (ROE) is expected to rise from 20% in 2023 to 26% by 2026, showcasing improved profitability [25]. Market Position - The company has a strong research and development capability, particularly in the field of children's health, with multiple provincial-level innovation platforms established [31]. - The company’s stock has shown a relative performance of -1.0% over the last month, but a significant increase of 26.0% over the last three months, indicating a positive trend in the medium term [31].